ASX:BXB.AX 19 February 2026

Brambles shares jump after cash-flow guidance upgrade — what ASX investors watch next

Brambles shares rose 3.7% to A$24.38 after the company raised its full-year free cash flow outlook and declared a 21% higher interim dividend. Half-year sales revenue climbed 2% to US$3.53 billion, with underlying profit up 7% to US$792 million. The buyback plan remains on track. Volumes were flat as weak consumer demand offset new business gains.

19 February 2026

ASX:BXB.AX·Earnings Reports·Stock Market

ImmunityBio IBRX Rises on Anktiva Growth but Valuation Risks Loom
March 13, 2026, 3:12 PM EDT. ImmunityBio's IBRX stock surged over 330% year-to-date as Anktiva's prescriptions accelerate and geographic expansion gains traction. The market prices the stock at a hefty 33x forward sales multiple, reflecting high expectations for rapid commercialization and flawless execution in reimbursement, manufacturing, and regulation. By comparison, sector peers trade at multiples near 2x sales, highlighting IBRX's premium. Despite this optimism, competition from cancer drug giants Merck and Bristol Myers Squibb in bladder cancer raises risks. Investors remain cautious with a Neutral rating and an $8.25 price target. Key factors that could shift this stance include sustained U.S. adoption, effective international launches, and progress on label expansions. The outlook hinges on ImmunityBio's ability to navigate these operational challenges successfully.